<![CDATA[Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026]]>

Advertisement Commentary|Articles|May 7, 2026 Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026 Author(s)Caroline Seymour Fact checked by: Kyle Doherty Listen0:00 / 0:00 Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois. Advertisement Before you leave for the 2026 ASCO Annual Meeting, which will take place from May 29 to June 2 in Chicago, Illinois, OncLive® pooled the presentations that leading medical oncologists in the field of lung cancer are prioritizing and why.This exclusive preview features insights from:Eric K. Singhi, MD, medical oncology faculty lead of the MD Anderson Young Onset Lung Cancer Program, Department of General Oncology, Division of Cancer Medicine, and assistant professor in the Department of General Oncology and Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston.Isabel Preeshagul, DO, MBS, associate attending physician at Memorial Sloan Kettering Cancer Center in New York, New York.Jonathan W. Lee, MD, MSc, chief hematology/oncology fellow in the Joan and Sanford I. Weill Department of Medicine at NewYork Presbyterian-Weill Cornell Medicine in New York, New York.Top Presentations to Watch at the 2026 ASCO Annual MeetingHR+ and HER2+ Breast CancerTriple-Negative Breast CancerSinghi’s list:Abstract 8502: Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN studyPresentation time: May 29, 2:00-2:12 PM CTLocation: Hall D2“At the 2024 ASCO Annual Meeting, we saw the 5-year follow-up data from the CROWN trial [NCT03052608] showing unprecedented PFS [progression-free survival] benefit, which became practice changing for many of our frontline [patients with] ALK-positive disease. [At this year’s meeting] we will hear about the 7-year follow-up data, which will continue to provide reasoning for frontline use of lorlatinib [Lorbrena].”Abstract 8515: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON studyPresentation time: May 30, 1:45-1:51 PM CTLocation: Hall D2“Many of us in thoracic oncology have long asked which patients we should prioritize a dual immunotherapy strategy for as opposed to single-agent immune checkpoint blockade plus chemotherapy. This study addresses this question for patients with a specific biomarker subset of [mutant] STK11/KEAP1 and/or KRAS, which is a disease that is largely thought to be immunotherapy resistant.”Abstract LBA3: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion–positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trialPresentation time: May 31, 2:13-2:25 PM CTLocation: Hall B1“If positive, this trial will establish a new standard of care for patients with early-stage, resected RET fusion–positive NSCLC [non–small cell lung cancer] and will meaningfully add to our treatment armamentarium of targeted therapies/precision medicine in the early-stage setting.”Preeshagul’s list:Abstract 8502: Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN studyPresentation time: May 29, 2:00-2:12 PM CTLocation: Hall D2“[We’re going to see the] 7-year follow-up data from the CROWN trial. At 5 years, the median PFS was not reached. [We saw] CNS [central nervous system] protection up to 92%, and 60% [of patients] had no cancer growth at 5 years. This is important as it shows durable response in the stage IV setting. [We] always appreciate longer follow-up data.”Abstract LBA3: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion–positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trialPresentation time: May 31, 2:13-2:25 PM CTLocation: Hall B1“[I’m] excited to hear about moving more targeted agents to the early-stage setting to hopefully improve survival and decrease risk of recurrence.”Abstract LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trialPresentation time: May 31, 2:47-2:59 PM CTLocation: Hall B1“[I’m] looking forward to hearing about how we can best treat these patients with stage IV squamous cell histology. [Based on the results] combination therapy may be the answer.”Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST)Presentation time: June 1, 1:15-1:27 PM CTLocation: Hall D1“[This is a] large study looking at the benefit of an adjuvant IO [immuno-oncology drug] plus chemotherapy in this patient cohort. While the space of neoadjuvant therapy is expanding, there still are patients who are not referred or unexpectedly require adjuvant therapy.”Lee’s list:Abstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28)Presentation time: May 29, 1:00-1:12 PM CTLocation: Hall D2“Non-classical EGFR-mutated NSCLC represents a challenging subset of lung cancer due to its heterogeneity and limited treatment options. I’m excited to see the first-line data comparing sunvozertinib with traditional platinum-based chemotherapy as well as additional efficacy and safety signals in higher-risk disease. I think this trial opens the door to combination approaches, similar to what we’ve seen in the classical EGFR-mutated space, which ultimately means more options and personalization for our patients.”Abstract 8513: Phase 2 data from ROSETTA Lung-02, a global randomized phase 2/3 trial of pumitamig (PD-L1 × VEGF-A bsAb) + chemotherapy in 1L NSCLCPresentation time: May 30, 1:21-1:27 PM CTLocation: Hall D2“Pumitamig is a bispecific antibody targeting PD-L1 and VEGF-A and to me is exciting for 2 reasons. First, as a class of drug, bispecific antibodies are intriguing from a mechanistic standpoint with a lot of ongoing research with respect to how simultaneous activation of pathways has implications on activity and efficacy. Second, there’s renewed excitement in targeting VEGF, which has been a target across multiple cancer types due to the interplay between angiogenesis and immune regulation.”Abstract 8012: Preliminary results from an ongoing phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNECPresentation time: May 31, 5:00-5:06 PM CTLocation: Arie Crown Theater“CAR T-cell therapy in solid tumors is still finding its footing, but it is truly exciting to see the growing role of cell therapy in solid tumors. We’ve seen the transformative potential of these therapies in the malignant hematology space, and I sincerely hope we can bring that degree of clinical benefit to our patients too.”Lee’s honorable mentions:Abstract 8517: Prophylactic peptide vaccine targeting resistance mutations in advanced ALK-positive lung cancer: Primary analysis from the ARCHER trialPresentation time: May 30, 2:09-2:15 PM CTLocation: Hall D2Abstract 8506: Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PDL1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 studyPresentation time: May 29, 3:12-3:24 PM CTLocation: Hall D2Abstract 8014: Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC)Presentation time: May 31, 5:12-5:18 PM CTLocation: Arie Crown Theater“These 3 [abstracts] are also pretty interesting to me, and I think folks [are] excited [to see] the clinical data for OptiTROP-Lung05 [NCT06448312].” NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementMentorship Is Key to Advance the Next Generation of Oncology ResearchersByKyle Doherty May 7th 2026Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts WarnByKyle Doherty May 7th 2026Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerByCourtney FlahertyMay 7th 2026Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.BySylvester Comprehensive Cancer CenterMay 7th 2026FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative DiseaseByChris RyanMay 7th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 20262Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer3ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies4FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease5Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn